Effect of remdesivir on mortality rate and clinical status of COVID-19 patients: a systematic review with meta-analysis

References

• Pagliano P, Sellitto C, Conti V, et al. Characteristics of viral pneumonia in the COVID-19 era: an update. Infection. 2021;49(4):607–616.
   PubMed Web of Science ®Google Scholar
• WHO Coronavirus (COVID-19) Dashboard [cited 2022 Mar 7]. Available from: https://covid19.who.int/.
   Google Scholar
• Brouwer MC, Ascione T, Pagliano P. Neurologic aspects of covid-19: a concise review. Infez Med. 2020;28(suppl 1):42–45.
   PubMedGoogle Scholar
• Boglione L, Corcione S, Shbaklo N, et al. Liver involvement and mortality in COVID-19: a retrospective analysis from the CORACLE study group. Infez Med. 2022;30(1):80–85.
   PubMedGoogle Scholar
• Alali AH, Smaisem MS, Alsheikh AM, et al. Myocardial injuries among patients with COVID-19: a systematic review. Infez Med. 2021;29(3):345–354.
   PubMedGoogle Scholar
• Pagliano P, Scarpati G, Sellitto C, et al. Experimental pharmacotherapy for COVID-19: the latest advances. J Exp Pharmacol. 2021;13:1–13.
   PubMedGoogle Scholar
• Aslan AT, Akova M. Current status of therapeutic alternatives for COVID-19: a narrative review. Infez Med. 2021;29(3):312–327.
   PubMedGoogle Scholar
• Costantino M, Sellitto C, Conti V, et al. Adverse events associated with BNT162b2 and AZD1222 vaccines in the real world: surveillance report in a single Italian vaccine center. JCM. 2022;11(5):1408.
   Google Scholar
• Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with covid-19. N Engl J Med. 2021;384:693–704.
   PubMed Web of Science ®Google Scholar
• Conti V, Corbi G, Sellitto C, et al. Effect of tocilizumab in reducing the mortality rate in COVID-19 patients: a systematic review with meta-analysis. JPM. 2021;11(7):628.
   Google Scholar
• Vela D, Vela-Gaxha Z, Rexhepi M, et al. Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials. Br J Clin Pharmacol. 2022;88(5):1955–1963.
   PubMed Web of Science ®Google Scholar
• Pagliano P, Sellitto C, Scarpati G, et al. An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19). Expert Opin Drug Discov. 2022;17(1):9–18.
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271.
   PubMed Web of Science ®Google Scholar
• Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9(2):e00221-18.
   PubMed Web of Science ®Google Scholar
• Williamson BN, Feldmann F, Schwarz B, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020;585(7824):273–276.
   PubMed Web of Science ®Google Scholar
• FDA Approves First COVID-19 Vaccine [cited 2022 Mar 7]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19.
   Google Scholar
• Veklury | European Medicines Agency - European Union [cited 2022 Mar 7]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/veklury.
   Google Scholar
• FDA Takes Actions to Expand Use of Treatment for Outpatients with Mild-to-Moderate COVID-19 [cited 2022 Mar 7]. Available from: https://www.fda.gov/news-events/press-announcements/fda-takes-actions-expand-use-treatment-outpatients-mild-moderate-covid-19.
   Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19: final report. N Engl J Med. 2020;383(19):1813–1826.
   PubMed Web of Science ®Google Scholar
• Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for covid-19: interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497–511.
   PubMed Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–2012.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and Meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• The Newcastle-Ottawa Scale (NOS) for assessing the quality of non randomised studies in meta-analyses [cited 2022 Mar 7]. Available online: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
   Google Scholar
• Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence–study limitations (risk of bias). J Clin Epidemiol. 2011;64(4):407–415.
   PubMed Web of Science ®Google Scholar
• Rosenblad A. Introduction to Meta-Analysis by Michael Borenstein, Larry V. Hedges, Julian P.T. Higgins, Hannah R. Rothstein. Int Statist Rev. 2009;77(3):478–479.
   Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statist Med. 2002;21(11):1539–1558.
   PubMed Web of Science ®Google Scholar
• Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 The Cochrane Collaboration [cited 2022 Mar 7]. Available from: www.training.cochrane.org/handbook.
   Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
   PubMed Web of Science ®Google Scholar
• Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048–1057.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578.
   PubMed Web of Science ®Google Scholar
• Arch BN, Kovacs D, Scott JT, et al. Evaluation of the effectiveness of remdesivir in treating severe COVID-19 using data from the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, national cohort study. medRxiv 2021.06.18.21259072.
   Google Scholar
• Mozaffari E, Chandak A, Zhang Z, et al. Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort. Clin Infect Dis. 2021;2021:ciab875.
   Google Scholar
• Olender SA, Perez KK, Go AS, et al. Remdesivir for severe coronavirus disease 2019 (COVID-19) versus a cohort receiving standard of care. Clin Infect Dis. 2021;73(11):e4166–e4174.
   PubMed Web of Science ®Google Scholar
• Pasquini Z, Montalti R, Temperoni C, et al. Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU. J Antimicrob Chemother. 2020;75(11):3359–3365.
   PubMed Web of Science ®Google Scholar
• Russo A, Binetti E, Borrazzo C, et al. Efficacy of remdesivir-containing therapy in hospitalized COVID-19 patients: a prospective clinical experience. JCM. 2021;10(17):3784.
   Google Scholar
• Benfield T, Bodilsen J, Brieghel C, et al. Improved survival among hospitalized patients with coronavirus disease 2019 (COVID-19) treated with remdesivir and dexamethasone. A nationwide population-based cohort study. Clin Infect Dis. 2021;73(11):2031–2036.
   PubMed Web of Science ®Google Scholar
• Flisiak R, Zarębska-Michaluk D, Berkan-Kawińska A, et al. Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study. Pol Arch Intern Med. 2021;131(1):103–110.
   PubMedGoogle Scholar
• WHO R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis [cited 2022 Mar 7]. Available from: https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf.
   Google Scholar
• Esposito S, Noviello S, Pagliano P. Update on treatment of COVID-19: ongoing studies between promising and disappointing results. Infez Med. 2020;28(2):198–211.
   PubMedGoogle Scholar
• Gholizadeh P, Safari R, Marofi P, et al. Alteration of liver biomarkers in patients with SARS-CoV-2 (COVID-19). J Inflamm Res. 2020;13:285–292.
   PubMed Web of Science ®Google Scholar
• Pagliano P, Spera AM, Ascione T, et al. Infections causing stroke or stroke-like syndromes. Infection. 2020;48(3):323–332.
   PubMed Web of Science ®Google Scholar
• Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929–936.
   PubMed Web of Science ®Google Scholar
• Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe covid-19 in outpatients. N Engl J Med. 2022;386(4):305–315.
   PubMed Web of Science ®Google Scholar
• Kaka AS, MacDonald R, Linskens EJ, et al. Major update 2: remdesivir for adults with COVID-19: a living systematic review and meta-analysis for the American College of Physicians Practice Points. Ann Intern Med. 2022;175(5):701–709.
   PubMed Web of Science ®Google Scholar
• Dezza FC, Oliva A, Mauro V, et al. Real-life use of remdesivir-containing regimens in COVID-19: a retrospective case-control study. Infez Med. 2022;30(2):211–222.
   PubMedGoogle Scholar
• Marrone A, Nevola R, Sellitto A, et al. Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of COVID-19 patients requiring supplemental O2 therapy: a prospective controlled non-randomized study. Clin Infect Dis. 2022;2022:ciac014.
   Google Scholar
• Tan YL, Tan KSW, Chu JJH, et al. Combination treatment with remdesivir and ivermectin exerts highly synergistic and potent antiviral activity against murine coronavirus infection. Front Cell Infect Microbiol. 2021;11:700502.
   PubMed Web of Science ®Google Scholar
• Schultz DC, Johnson RM, Ayyanathan K, et al. Pyrimidine biosynthesis inhibitors synergize with nucleoside analogs to block SARS-CoV-2 infection. 2021; Preprint. bioRxiv. 2021.06.24.449811.
   Google Scholar
• Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with covid-19. N Engl J Med. 2021;384(9):795–807.
   PubMed Web of Science ®Google Scholar